Pulmocide

Pulmocide Focuses on the Development of Respiratory Disease Drugs; Pulmocide Has Two Products, One of Which is PC786. PC786 Can Be Administered as an Aerosol Formulation to be Inhaled by Patients for the Treatment of Respiratory Syncytial Virus Infection. Due to Its Formulation Characteristics, PC786 Can Directly Reach the Bronchial Epithelium, Rapidly Take Effect at a High Local Concentration, and Prevent the Development of Drug Resistance. The Other Product, PC945, Targets Fungal Infections in the Lungs. Customized Inhalable Drugs Are Currently Under Development to Provide Safe and Effective Therapies for Patients Suffering from Respiratory Syncytial Virus Infection or Pulmonary Fungal Infections.